SPDE Speedus Corp (CE)

PRINCETON, N.J., Nov. 6 /PRNewswire/ -- Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI) and a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), today announced that it has been awarded a $101,000 contract by the U.S. Army to develop pilot-versions of a telemedicine system for use in cardiology. Under the terms of the contract, Zargis will develop prototypes of a system designed to record, synchronize and analyze heart sounds, lung sounds and ECG signals in pediatric patients who are being cared for by remote military treatment facilities. The system will be fully integrated with an existing Army telehealth platform. "We're very pleased that Zargis has been selected to enhance the Army's telehealth platform," stated Zargis CEO John Kallassy. "This project builds upon our expertise in computer-aided auscultation and we expect it to result in additional opportunities for Zargis involving military and civilian telemedicine initiatives." About Zargis Medical Corp. Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds. About Cardioscan(R) Zargis has developed Cardioscan, the first and only computer-assisted medical device designed to support physicians in analyzing heart sounds for the identification of suspected systolic and diastolic murmurs. Cardioscan is a non-invasive device that is easy to use, portable, and takes just minutes to perform. The device implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. Cardioscan provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. As a result, Cardioscan enhances auscultation-a procedure that has been universally employed through a stethoscope for nearly two-hundred years. For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or or visit the following Web sites: http://www.zargis.com/ and http://www.speedus.com/. Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. DATASOURCE: Zargis Medical Corp. CONTACT: Peter Hodge of Zargis Medical Corp., 1-888-773-3669 ext. 23, Web site: http://www.zargis.com/ http://www.speedus.com/

Copyright